Pathogenetic therapy of COVID-19: focus on glucocorticoids

Authors

  • M.V. Bondar Shupyk National University of Healthcare of Ukraine, Kyiv, Ukraine
  • M.M. Pilipenko Shupyk National University of Healthcare of Ukraine, Kyiv, Ukraine
  • T.V. Ovsiienko Shupyk National University of Healthcare of Ukraine, Kyiv, Ukraine; State Institution “Academician O.F. Vozianov Institute of Urology” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • O.A. Loskutov Shupyk National University of Healthcare of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0002-7646-9193

DOI:

https://doi.org/10.22141/2224-0586.18.2.2022.1466

Keywords:

COVID-19, systemic inflammatory response, pro-inflammatory cytokines, hypothalamo-pituitary-adrenal system, glucocorticoids, review

Abstract

The problem of preventing excessive production of pro-inflammatory cytokines in the case of COVID-19 remains unresolved. The use of steroids in the treatment of coronavirus pneumonia remains controversial. To date, there is insufficient literature data for the routine use of steroids in COVID-19 intensive care programs, and this issue remains the subject of continuous research and endless debate. The review of the scientific literature focuses on one of the areas of pathogenetic therapy for COVID-19 — the prevention and elimination of hyperproduction of pro-inflammatory cytokines using glucocorticoid drugs. The review presents modern international recommendations on the use of glucocorticoid drugs in severe COVID-19, examines the pathogenetic mechanisms of their action and side effects.

Downloads

Download data is not yet available.

References

Bellani G, Laffey JG, Pham T, et al; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291.

Elnoby AS. Clinical Consideration of Glucocorticoids in COVID-19. J Pharm Pract. 2021 Apr;34(2):181-182. doi: 10.1177/0897190020987124.

Alexaki VI, Henneicke H. The Role of Glucocorticoids in the Management of COVID-19. Horm Metab Res. 2021 Jan;53(1):9-15. doi: 10.1055/a-1300-2550.

Timmermans S, Souffriau J, Libert C. A General Introduction to Glucocorticoid Biology. Front Immunol. 2019 Jul 4;10:1545. doi: 10.3389/fimmu.2019.01545.

Widén C, Gustafsson JA, Wikström AC. Cytosolic glucocorticoid receptor interaction with nuclear factor-kappa B proteins in rat liver cells. Biochem J. 2003 Jul 1;373(Pt 1):211-20. doi: 10.1042/BJ20030175.

Panettieri RA, Schaafsma D, Amrani Y, Koziol-White C, Ostrom R, Tliba O. Non-genomic Effects of Glucocorticoids: An Updated View. Trends Pharmacol Sci. 2019 Jan;40(1):38-49. doi: 10.1016/j.tips.2018.11.002.

Vandewalle J, Libert C. Glucocorticoids in Sepsis: To Be or Not to Be. Front Immunol. 2020 Jul 21;11:1318. doi: 10.3389/fimmu.2020.01318.

Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017 Apr;17(4):233-247. doi: 10.1038/nri.2017.1.

Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027.

Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul. 2021 Aug;81:100818. doi: 10.1016/j.jbior.2021.100818.

Quatrini L, Ugolini S. New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol. 2021 Feb;18(2):269-278. doi: 10.1038/s41423-020-00526-2.

Tu GW, Shi Y, Zheng YJ, et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J Transl Med. 2017 Aug 29;15(1):181. doi: 10.1186/s12967-017-1284-7.

Ferrara F, Vitiello A. Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedebergs Arch Pharmacol. 2021 May;394(5):1003-1007. doi: 10.1007/s00210-021-02049-7.

Yaqoob H, Greenberg D, Hwang F, et al. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit. J Med Virol. 2022 Jan;94(1):349-356. doi: 10.1002/jmv.27351.

Normand ST. The RECOVERY Platform. N Engl J Med. 2021 Feb 25;384(8):757-758. doi: 10.1056/NEJMe2025674.

RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436.

Li H, Yan B, Gao R, Ren J, Yang J. Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies. Int Immunopharmacol. 2021 Nov;100:108121. doi: 10.1016/j.intimp.2021.108121.

Qiu T, Liang S, Dabbous M, Wang Y, Han R, Toumi M. Chinese guidelines related to novel coronavirus pneumonia. J Mark Access Health Policy. 2020 Oct 8;8(1):1818446. doi: 10.1080/20016689.2020.1818446.

Bai C, Chotirmall SH, Rello J, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). Eur Respir Rev. 2020 Oct 5;29(157):200287. doi: 10.1183/16000617.0287-2020.

Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478. doi: 10.1093/cid/ciaa478.

National Institutes of Health. COVID-19 Treatment Guidelines Corticosteroids. Accessed: 2020 Oct 17. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/.

Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5.

World Health Organization. Corticosteroids for COVID-19. WHO. Accessed: 2020 Oct 17. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1.

Marik PE, Kory P, Varon J, Iglesias J, Meduri GU. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. Expert Rev Anti Infect Ther. 2021 Feb;19(2):129-135. doi: 10.1080/14787210.2020.1808462.

Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar;165(1):1-7. doi: 10.5507/bp.2021.011.

Ding Y, Wang H, Shen H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003 Jul;200(3):282-9. doi: 10.1002/path.1440.

Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007 Apr;170(4):1136-47. doi: 10.2353/ajpath.2007.061088.

Leyendecker P, Ritter S, Riou M, et al. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol. 2021 Feb;31(2):895-900. doi: 10.1007/s00330-020-07226-5.

Frankel M, Feldman I, Levine M, et al. Bilateral Adrenal Hemorrhage in Coronavirus Disease 2019 Patient: A Case Report. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa487. doi: 10.1210/clinem/dgaa487.

Heidarpour M, Vakhshoori M, Abbasi S, Shafie D, Rezaei N. Adrenal insufficiency in coronavirus disease 2019: a case report. J Med Case Rep. 2020 Aug 24;14(1):134. doi: 10.1186/s13256-020-02461-2.

Téblick A, Langouche L, Van den Berghe G. Anterior pituitary function in critical illness. Endocr Connect. 2019 Aug 1;8(8):R131-R143. doi: 10.1530/EC-19-0318.

Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar;165(1):1-7. doi: 10.5507/bp.2021.011.

Panesar NS, Lam CW, Chan MH, Wong CK, Sung JJ. Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol. Eur J Clin Invest. 2004 May;34(5):382-4. doi: 10.1111/j.1365-2362.2004.01347.x.

Published

2022-04-30

How to Cite

Bondar, M., Pilipenko, M., Ovsiienko, T., & Loskutov, O. (2022). Pathogenetic therapy of COVID-19: focus on glucocorticoids. EMERGENCY MEDICINE, 18(2), 6–12. https://doi.org/10.22141/2224-0586.18.2.2022.1466

Issue

Section

Scientific Review

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 > >>